Arcutis Biotherapeutics Announces Upcoming Investor Participation
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), known for its innovative contributions in immuno-dermatology, has exciting news regarding its participation in several forthcoming investor conferences. This initiative represents the company's ongoing commitment to fostering relationships with investors and sharing important updates regarding their progress and future endeavors.
Details of Upcoming Conferences
Arcutis management will engage in discussions at three key investor conferences where they will share insights into their advancements and future goals. Here’s what to expect:
Citi’s 2025 Biopharma Back to School Conference
This conference is scheduled for September 2-3, 2025. The highlighted event will feature a fireside chat on September 3rd at 9:45 AM EDT. This session provides investors with a unique opportunity to engage with Arcutis leaders as they delve into recent developments in their pipeline and strategic outlook.
Morgan Stanley’s 23rd Annual Global Healthcare Conference
Taking place from September 8-10, 2025, this conference will include a crucial fireside chat on September 9 at 2:35 PM EDT. Attendees will gain insight into how Arcutis is addressing significant challenges in dermatological care, further emphasizing its dedication to patient well-being and therapeutic innovation.
HC Wainwright 27th Annual Global Investment Conference
Also occurring from September 8-10, 2025, Arcutis will participate in this event, specifically on September 10 at 10:30 AM EDT. This conference is another prime opportunity for investors to hear directly from Arcutis about the growth of its product offerings and the impacts these have on patient populations.
Accessing the Webcasts
For those who cannot attend, Arcutis will provide webcasts of these conferences accessible via the Events section on the company’s official website. Replays of these sessions will be available for 180 days post-conference, ensuring that interested parties can access this valuable information at their convenience.
About Arcutis
Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology entity, is dedicated to innovation aimed at improving the lives of individuals with immune-mediated dermatological diseases. With an expanding portfolio of advanced therapies, Arcutis addresses critical needs in the treatment of major inflammatory skin conditions. Leveraging a unique dermatological development platform, the company continues to focus on creating differentiated therapies supported by scientifically validated targets, enhancing its pipeline for inflammatory dermatological conditions.
Frequently Asked Questions
What upcoming conferences will Arcutis participate in?
Arcutis will participate in Citi's 2025 Biopharma Conference, Morgan Stanley's Global Healthcare Conference, and HC Wainwright's Global Investment Conference.
When will the fireside chats take place?
The fireside chats are scheduled for September 3rd, September 9th, and September 10th at various times.
How can I access the webcasts of these conferences?
The webcasts can be accessed in the Events section of Arcutis's official website and will also be available for replay for 180 days following the conferences.
What is the focus of Arcutis Biotherapeutics?
Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases, offering advanced solutions for patients facing major inflammatory skin conditions.
Who should I contact for more information?
For media inquiries, you can contact Amanda Sheldon, Head of Corporate Communications. For investor inquiries, reach out to Brian Schoelkopf.
